Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Lymphoma 223Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Non-Hodgkin 148Leukemia, Lymphocytic, Chronic, B-Cell 138Lymphoma, Follicular 130Lymphoma, Mantle-Cell 117Lymphoma, B-Cell, Marginal Zone 78Leukemia 72Burkitt Lymphoma 62Waldenstrom Macroglobulinemia 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Lymphoma, B-Cell 45Recurrence 39Lymphoma, Large-Cell, Immunoblastic 33Hodgkin Disease 26Neoplasms 16Dendritic Cell Sarcoma, Interdigitating 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Hairy Cell 12Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Accelerated Phase 8Intraocular Lymphoma 8Neoplasms, Plasma Cell 7Leukemia, Myelomonocytic, Chronic 7

Interventions

fludarabine 4Rituximab 4ibrutinib 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Cyclophosphamide 3Busulfan 3Bendamustine Hydrochloride 3fludarabine phosphate 2Patient Reported Outcome Measures 2Mesna 2venetoclax 1sargramostim 1pirtobrutinib 1ofatumumab 1mocetinostat 1lirilumab 1copanlisib 1Thiotepa 1Sirolimus 1RFT5-SMPT-dgA immunotoxin 1Mitoxantrone 1Methotrexate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphoid × Rituximab × Clear all
NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

University of Wisconsin, Madison

Phase 2 Completed
36 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Washington

Phase 2 Terminated
1 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02481297 2020-05-28

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
7 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00609869 2015-09-17

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡